SBSB
TCRT icon

Sullivan, Bruyette, Speros & Blaney’s Alaunos Therapeutics TCRT Stock Holding History

Sullivan, Bruyette, Speros & Blaney’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-67
Closed -$42K – 173
2017
Q4 		$42K Hold
67
– – ﹤0.01% 164
2017
Q3 		$62K Hold
67
– – 0.01% 158
2017
Q2 		$63K Sell
67
-3
-4% -$2.94K 0.01% 146
2017
Q1 		$67K Hold
70
– – 0.01% 146
2016
Q4 		$57K Hold
70
– – 0.01% 142
2016
Q3 		$59K Hold
70
– – 0.01% 140
2016
Q2 		$58K Buy
+70
New +$76.2K 0.01% 137

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Sullivan, Bruyette, Speros & Blaney's TCRT Position: Q1 2018 in Review

Sullivan, Bruyette, Speros & Blaney sold out of Alaunos Therapeutics (TCRT) in Q1 2018, closing a stake of 67 shares — an estimated $42K sold.

Sullivan, Bruyette, Speros & Blaney first reported a position in TCRT in Q2 2016 and held it in 7 quarters. The position peaked at $67K in Q1 2017. 133 funds tracked by Wall St. Rank hold TCRT as of Q1 2018.

  • Sullivan, Bruyette, Speros & Blaney reported no remaining Alaunos Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Sullivan, Bruyette, Speros & Blaney sold 67 Alaunos Therapeutics shares in Q1 2018, an estimated $42K.
  • Sullivan, Bruyette, Speros & Blaney first reported a position in Alaunos Therapeutics in Q2 2016 and held it in 7 quarters.
  • Sullivan, Bruyette, Speros & Blaney's Alaunos Therapeutics position peaked at $67K in Q1 2017.
  • 133 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2018.

Based on Sullivan, Bruyette, Speros & Blaney's 13F filing for Q1 2018, filed 8 May 2018.